


Form PTO-1449 <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	Docket Number 304142000201	Application Number To Be Assigned
	Applicant Malaya Chatterjee et al. <b>09/293533</b>	
	Filing Date Herewith	Group Art Unit To Be Assigned

**ATTACHMENT # 3**

**U.S. PATENT DOCUMENTS**

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
LCS	1.	08/05/97	5,653,977	Saleh	—	—	
LCA	2.	06/23/87	4,675,287	Reisfeld et al.	—	—	
LCA	3.	09/15/87	4,693,966	Houghton et al.	—	—	
LCA	4.	02/02/88	4,722,840	Valenzuela et al.	—	—	
LCA	5.	07/18/89	4,849,509	Thurin et al.	—	—	
LCA	6.	02/27/90	4,904,596	Hakomori	—	—	
LCA	7.	04/17/90	4,918,164	Hellstrom et al.	—	—	
LCA	8.	04/23/91	5,009,995	Albino et al.	—	—	
LCA	9.	10/01/91	5,053,224	Koprowski et al.	—	—	
LCA	10.	10/15/91	5,057,540	Kensil et al.	—	—	
LCA	11.	02/25/92	5,091,177	Hellstrom et al.	—	—	
LCA	12.	04/07/92	5,102,663	Livingston et al.	—	—	
LCA	13.	07/28/92	5,134,075	Hellstrom et al.	—	—	
LCA	14.	08/25/92	5,141,742	Brown et al.	—	—	
LCA	15.	05/04/93	5,208,146	Irie	—	—	
LCA	16.	08/31/93	5,240,833	Nudelman et al.	—	—	
LCA	17.	09/07/93	5,242,824	Hellstrom et al.	—	—	
LCA	18.	12/14/93	5,270,202	Raychaudhuri	—	—	
LCA	19.	05/03/94	5,308,614	Hakomori	—	—	
LCA	20.	06/25/96	5,529,922	Chapman et al.	—	—	
LCA	21.	11/05/96	5,571,900	Wiegand et al.	—	—	
LCA	22.	03/18/97	5,612,030	Chatterjee et al.	—	—	

EXAMINER: 	DATE CONSIDERED: <b>2/13/02</b> <b>10/30/00</b>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 304142000201	Application Number To Be Assigned
	Applicant Malaya Chatterjee et al. <b>09/293533</b>	
	Filing Date Herewith	Group Art Unit To Be Assigned


### FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
LH	23.	02/13/86	WO 86/00909	PCT	—	—		
↓	24.	05/16/90	0368131	Europe	↓	↓		
	25.	11/12/92	WO 92/19266	PCT				
	26.	09/08/93	0280209	Europe				
	27.	08/04/94	WO 94/16731	PCT				
	28.	10/13/94	WO 94/22479	PCT				
	29.	02/16/95	WO 95/04548	PCT				
	30.	07/05/95	0661061	Europe	↓	↓		
↓	31.	12/21/95	WO 95/34638	PCT	↓	↓		
LH	32.	07/25/96	WO 96/22373	PCT	—	—		

### OTHER DOCUMENTS

*(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
LH	33.	Derwent® Survey of EP 0368131 (05/16/90).
↓	34.	1A7 Heavy Chain Protein Genbank Search. 1995
	35.	1A7 Light Chain Protein Genbank Search. 1995
	36.	1A7 Heavy Chain DNA Genbank Search. 1995
	37.	1A7 Light Chain DNA Genbank Search. 1995
	38.	Angeles et al., "Isoabzymes: Structurally and mechanistically similar catalytic antibodies from the same immunization" <u>Biochemistry</u> (1993) 32:12128-12135.
	39.	Bhattacharya-Chatterjee et al., "Anti-idiotypic antibodies as potential therapeutic agents for human breast cancer" <u>In Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment, Conference on Breast Cancer Therapy Immunology</u> , R.L. Ceriani (Ed.), Plenum Press, N.Y., pages 139-148, 1994.
↓	40.	Bhattacharya-Chatterjee et al., "Idiotypic vaccines against human T cell acute lymphoblastic leukemia. I. Generation and characterization of biologically active monoclonal anti-idiotypes" <u>J. Immunol.</u> (1987) 139:1354-1360.
LH	41.	Bhattacharya-Chatterjee et al., "Idiotypic vaccines against human T-cell leukemia" <u>J. Immunol.</u> (1988) 141:1398-1403.

EXAMINER: 	DATE CONSIDERED: 2/13/02
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 304142000201	Application Number To Be Assigned
		Applicant  <div style="text-align: right;">Malaya Chatterjee et al. 09/253533</div>	
		Filing Date Herewith	Group Art Unit To Be Assigned
<b>OTHER DOCUMENTS</b> <span style="float: right;"><i>(including author, title, Date, Pertinent Pages, Etc.)</i></span>			
Examiner Initials	Ref. No.	Title	
LA	42.	Bhattacharya-Chatterjee et al., "Idiotypic antibody immunotherapy of cancer" <u>Cancer Immunol. Immunother.</u> (1994) 38:75-82.	
	43.	Bhattacharya-Chatterjee et al., "Murine monoclonal anti-idiotypic antibody as a potential network antigen for human carcinoembryonic antigen" <u>J. Immunol.</u> (1990) 145:2758-2765.	
	44.	<del>Bhattacharya-Chatterjee et al., "Syngeneic monoclonal anti-idiotypic antibodies against a monoclonal antibody to human melanoma-associated antigen" <u>J. Immunol.</u> (1993) 150:142A (Abstract 805).</del>	
	45.	Bird et al., "Single-chain antigen-binding proteins" <u>Science</u> (1988) 242:423-426.	
	46.	Blier et al., "A limited number of B cell lineages generates the heterogeneity of a secondary immune response" <u>J. Immunol.</u> (1987) 139:3996-4006.	
	47.	Chakraborty et al., "Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotypic antibody" <u>Cancer Res.</u> (1995) 55:1525-1530.	
	48.	Chapman et al., "Induction of IgG antibodies against G <sub>D2</sub> ganglioside in rabbits by an anti-idiotypic monoclonal antibody" <u>J. Clin. Invest.</u> (1991) 88:186-192.	
	49.	Charbonnier et al., "Structural convergence in the active sites of a family of catalytic antibodies" <u>Science</u> (1997) 275:1140-1142.	
	50.	Chattopadhyay et al., "Murine monoclonal anti-idiotypic antibody breaks unresponsiveness and induces a specific antibody response to human melanoma-associated proteoglycan antigen in cynomolgus monkeys" <u>Proc. Natl. Acad. Sci. USA</u> (1992) 89:2684-2688.	
	51.	Cheresh et al., "Biosynthesis and expression of the disialoganglioside G <sub>D2</sub> , a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytotoxicity" <u>Cancer Res.</u> (1996) 46:5112-5118.	
	52.	Cheresh et al., "Disialoganglioside G <sub>D2</sub> and G <sub>D3</sub> are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins" <u>J. Cell. Biol.</u> (1986) 102:688-696.	
	53.	Cheresh et al., "Disialoganglioside GD <sub>2</sub> distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin" <u>J. Cell. Biol.</u> (1986) 102:1887-1897.	
	54.	Cheresh et al., "Localization of the gangliosides G <sub>D2</sub> and G <sub>D3</sub> in adhesion plaques and on the surface of human melanoma cells" <u>Proc. Natl. Sci. USA</u> (1984) 81:5767-5771.	
	55.	Cheung et al., "Antibody response to murine anti-G <sub>D2</sub> monoclonal antibodies: correlation with patient survival" <u>Cancer Res.</u> (1994) 54:2228-2233.	
7	56.	<del>Cheung et al., "Disialoganglioside G<sub>D2</sub> anti-idiotypic monoclonal antibodies" <u>Int. J. Cancer</u> (1993) 54:499-505.</del>	
hmm	57.	Cheung et al., "Ganglioside G <sub>D2</sub> specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma" <u>J. Clin. Oncol.</u> (1987) 5(9):1430-1440.	
EXAMINER:		DATE CONSIDERED: 2/13/02	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449  <b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 304142000201	Application Number To Be Assigned  <div style="text-align: right; font-size: 1.2em;">09/293533</div>
Applicant  <div style="text-align: right;">Malaya Chatterjee et al.</div>		Filing Date Herewith  Group Art Unit To Be Assigned	

OTHER DOCUMENTS <span style="float: right; font-size: 0.8em;">(including author, title, Date, Pertinent Pages, Etc.)</span>		
Examiner Initials	Ref. No.	Title
LTP	58.	Cochran et al., "In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals" <u>J. Virol.</u> (1985) 54:30-37.
	59.	Conry et al., "A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity" <u>Gene Therapy</u> (1995) 2:59-65.
	60.	Foon et al., "Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotypic antibody vaccine" <u>J. Clin. Invest.</u> (1995) 96:334-342.
	61.	Foon et al., "Anti-idiotypic antibodies: novel therapeutic approach to cancer therapy" <u>Immunology Series</u> (1994) 61:281-292.
	62.	Guo et al., "Mechanistically different catalytic antibodies obtained from immunization with a single transition-state analog" <u>Proc. Natl. Acad. Sci. USA</u> (1995) 92:1694-1698.
	63.	Hamilton et al., "Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography" <u>Int. J. Cancer</u> (1993) 53:566-573.
	64.	Hamilton et al., "Ganglioside expression on sarcoma and small-cell lung carcinoma compared to tumors of neuroectodermal origin" <u>Proc. Am. Assoc. Cancer Res.</u> (1993) 34:491 (Abstract 2928).
	65.	Handgretinger et al., "A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14G2a" <u>Cancer Immunol. Immunother.</u> (1992) 35:199-204.
	66.	Hastings et al., "Production and characterization of a murine/human chimeric anti-idiotypic antibody that mimics ganglioside" <u>Cancer Res.</u> (1992) 52:1681-1686.
	67.	Hawkins et al., "A genetic approach to idiotypic vaccination" <u>J. Immunother.</u> (1993) 14:273-278.
	68.	Hawkins et al., "Plasmid vaccination against B-cell lymphoma" <u>Cancer Gene Therapy</u> (1994) 1(3):208.
	69.	Heidenheim et al., "CDw60, which identifies the acetylated form of GD <sub>3</sub> gangliosides, is strongly expressed in human basal cell carcinoma" <u>Brit. J. Dermatol.</u> (1995) 133:392-397.
	70.	Helling et al., "Ganglioside conjugate vaccines" <u>Mol. Chem. Neuropath.</u> (1994) 21:299-309.
	71.	Hruby et al., "Fine structure analysis and nucleotide sequence of the vaccinia virus thymidine kinase gene" <u>Proc. Natl. Acad. Sci. USA</u> (1983) 80:3411-3415.
	72.	<u>Imclone Systems Incorporated Annual Report, 1995.</u>
	73.	Irie et al., "Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2" <u>Proc. Natl. Acad. Sci. USA</u> (1986) 83:8694-8698.
	74.	Kanda et al., "Both V <sub>H</sub> and V <sub>L</sub> regions contribute to the antigenicity of anti-idiotypic antibody that mimics melanoma associated ganglioside GM <sub>3</sub> " <u>Cell Biophys.</u> (1994) 24/25:65-74.
LTP	75.	Kaufman et al., "A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)" <u>Int. J. Cancer</u> (1991) 48:900-906.

EXAMINER:	DATE CONSIDERED: 2/13/02
-----------	--------------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.


<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>	Docket Number 304142000201	Application Number To Be Assigned
	Applicant Malaya Chatterjee et al. <b>09/293533</b>	
	Filing Date Herewith	Group Art Unit To Be Assigned

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	76.	Leahy et al., "Sequences of 12 monoclonal anti-dinitrophenyl spin-label antibodies for NMR studies" <u>Proc. Natl. Acad. Sci. USA</u> (1988) <u>85</u> :3661-3665.
	77.	Livingston et al., "GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3" <u>Vaccine</u> (1993) <u>11</u> (12):1199-1204.
	78.	Livingston, "Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines" <u>Immunol. Rev.</u> (1995) <u>145</u> :147-166.
	79.	Mittelman et al., "Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma" <u>Proc. Natl. Acad. Sci. USA</u> (1992) <u>89</u> :466-470.
	80.	Mittelman et al., "Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23" <u>Cancer Research</u> (1994) <u>54</u> :415-421.
	81.	Miyashita et al., "A common ancestry for multiple catalytic antibodies generated against a single transition-state analog" <u>Proc. Natl. Acad. Sci. USA</u> (1994) <u>91</u> :6045-6049.
	82.	Moss, "Vaccinia virus: A tool for research and vaccine development" <u>Science</u> (1991) <u>252</u> :1662-1667.
	83.	Mujoo et al., "Disialoganglioside G <sub>D2</sub> on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytotoxicity and suppression of tumor growth" <u>Cancer Res.</u> (1987) <u>47</u> :1098-1104.
	84.	Mujoo et al., "Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside G <sub>D2</sub> antibody 14.18" <u>Cancer Res.</u> (1989) <u>49</u> :2857-2861.
	85.	Nahmias et al., "The immune response toward $\beta$ -adrenergic ligands and their receptors. VIII. Extensive diversity of V <sub>H</sub> and V <sub>L</sub> genes encoding anti-alprenolol antibodies" <u>J. Immunol.</u> (1988) <u>140</u> :1304-1311.
	86.	Posnett et al., "A novel method for producing anti-peptide antibodies" <u>J. Biol. Chem.</u> (1988) <u>263</u> :1719-1725.
	87.	Qin et al., "Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine" <u>Gene Therapy</u> (1996) <u>3</u> :59-66.
	88.	Reininger et al., "Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: Skin vasculitis and glomerulonephritis arise from distinct pathogenic mechanisms" <u>Proc. Natl. Acad. Sci. USA</u> (1990) <u>87</u> (24):10038-10042.

EXAMINER:	DATE CONSIDERED: <b>2/13/02</b>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	

<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE CITATION</b> <b>IN AN APPLICATION</b>  <i>(Use several sheets if necessary)</i>		Docket Number 304142000201	Application Number To Be Assigned  <div style="text-align: right; font-size: 1.2em;">09 293/333</div>
Applicant  <div style="text-align: right;">Malaya Chatterjee et al.</div>		Filing Date Herewith  Group Art Unit To Be Assigned	
<b>OTHER DOCUMENTS</b> <span style="float: right;"><i>(including author, title, Date, Pertinent Pages, Etc.)</i></span>			
Examiner Initials	Ref. No.	Title	
LJ	89.	Russell et al., "Plasmid vaccination to elicit anti-idiotypic immune responses against surface immunoglobulin-positive B-cell malignancies" <u>Brit. J. Haematology</u> (1994) <u>86</u> (No. Suppl. 1):74 (Abstract P146).	
	90.	<del>Saleh et al., "Generation of a human anti-idiotypic antibody that mimics the GD2 antigen" <u>J. Immunol.</u> (1993) <u>151</u>(6):3390-3398.</del>	
	91.	Saleh et al., "Phase I trial of the murine monoclonal anti-G <sub>D2</sub> antibody 14G2a in metastatic melanoma" <u>Cancer Res.</u> (1992) <u>52</u> :4342-4347.	
	92.	Seaver, "Monoclonal antibodies in industry: More difficult than originally thought" <u>Genetic Engineering News</u> (August 1994) pp. 10, 21.	
	93.	Sen et al., "Induction of IgG antibodies by an anti-idiotypic antibody mimicking disialoganglioside GD2" Galley Proof of article accepted for publication in <u>J. Immunother.</u> (1997), 9 pages total.	
	94.	Sen et al., "Murine monoclonal antibody-idiotype antibody breaks tolerance and induces specific antibody response to human disialoganglioside GD2 in cynomolgus monkeys" <u>Abstract presented at the 9th International Congress of Immunology</u> , San Francisco, California, July 23-29, A5250, page 885, 1995.	
	95.	Sen et al., "Murine monoclonal anti-idiotypic (Id) antibody induces specific humoral responses to the GD2 ganglioside in melanoma patients" <u>Abstract submitted for AAAAI/AAI/CIS Joint Meeting</u> , 1997.	
	96.	Spooner et al., "DNA vaccination for cancer treatment" <u>Gene Therapy</u> (1995) <u>2</u> :173-180.	
	97.	Stenzel-Poore et al., "Clonal diversity, somatic mutation, and immune memory to phosphocholine-keyhole limpet hemocyanin" <u>J. Immunol.</u> (1989) <u>143</u> :4123-4133.	
	98.	Tam, "High-density multiple antigen-peptide system for preparation of antipeptide antibodies" <u>Methods Enzymol.</u> (1989) <u>168</u> :7-15.	
	99.	Tang et al., "Genetic immunization is a simple method for eliciting an immune response" <u>Nature</u> (1992) <u>356</u> :152-154.	
	100.	Tsuchida et al., "Gangliosides of human melanoma" <u>J. Natl. Cancer Inst.</u> (1987) <u>78</u> :45-54.	
V	101.	Wang et al., "Immunization by direct DNA inoculation induces rejection of tumor cell challenge" <u>Human Gene Therapy</u> (1995) <u>6</u> :407-418.	
BQ	102.	Yamamoto et al., "Anti-idiotypic monoclonal antibody carrying the internal image of ganglioside GM3" <u>J. Natl. Cancer Inst.</u> (1990) <u>82</u> (22):1757-1760.	
<div style="font-size: 1.5em; margin: 0 auto;">  </div>			
EXAMINER:		DATE CONSIDERED: 2/13/02	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			